Dew Drops CBD

12/24/2025

CBD and THC didn't just affect cancer cells. They stopped them from spreading.
Scientists watched the compounds disrupt colony formation in ovarian cancer. One of the deadliest cancers. Slowed by a plant.
Still early. But the door just opened.
Shared for informational purposes only.
Source: ScienceDaily / Medical Cannabis Research

12/24/2025

Scientists weren't just observing cell death. They were watching something far more significant: metastasis prevention.

CBD and THC, the primary compounds in cannabis, didn't simply attack ovarian cancer cells. They disrupted their ability to form colonies—the critical process that allows cancer to spread and become lethal.

Ovarian cancer is among the deadliest malignancies precisely because it metastasizes aggressively, colonizing tissue before detection. By the time symptoms appear, it's often widespread. Survival rates plummet once it spreads.

What researchers observed was groundbreaking: these plant compounds interfered with cancer's colonization mechanism. Cells couldn't organize. Couldn't replicate efficiently. Couldn't establish the foothold required for metastasis.

A plant that humans have cultivated for millennia—dismissed, criminalized, stigmatized—might contain molecules that prevent one of medicine's most devastating cancers from spreading.

This isn't treatment-ready yet. It's early-stage research, laboratory observations, preliminary data. Clinical trials remain years away. Dosing, delivery methods, side effects—all unknown.

But the door didn't just crack open. It swung wide.

For decades, cannabis research was legally strangled, scientifically suppressed. Now that restrictions are lifting, discoveries are accelerating. We're finding therapeutic potential that was always there, just forbidden from investigation.

Ovarian cancer slowed by compounds from a plant. Not engineered in labs. Not synthetically designed. Just extracted from nature and observed doing what prohibition prevented us from discovering decades ago.

The question isn't whether plants hold medical answers. It's how many cures we delayed by refusing to look.

Source: Shared for information purposes only

12/23/2025

2-AG is one of the body’s first responders when the brain is threatened. When an insult happens, whether that is trauma, ischemia, inflammation, or excitotoxic stress, the brain does not wait for outside help. It makes its own medicine, fast. That medicine is 2-arachidonoylglycerol, better known as 2-AG.

2-AG is an endocannabinoid, a lipid-based signaling molecule produced on demand in the brain and nervous system. Unlike neurotransmitters that sit stored in vesicles waiting to be released, 2-AG is synthesized in real time from membrane lipids the moment neurons sense danger. That speed matters. It allows the ECS, our Master Regulator, to respond within seconds to injury and begin damage control before secondary injury cascades take over.

When released, 2-AG primarily activates CB1 receptors in the brain and CB2 receptors on immune and glial cells. At CB1, 2-AG reduces excessive glutamate release, which is one of the main drivers of neuronal death after injury. Too much glutamate overstimulates neurons until they burn out. 2-AG reduces that volume, protecting neurons from excitotoxic damage. At CB2, it calms inflammatory signaling, limiting microglial overactivation that would otherwise expand the injury zone.

2-AG also stabilizes the blood-brain barrier, reduces oxidative stress, and helps preserve mitochondrial function inside neurons. This keeps cells alive long enough to repair rather than collapse. In short, 2-AG does not directly repair damage; it creates a protective window in which repair is possible.

This mechanism was clearly demonstrated in the peer-reviewed study “Endocannabinoid 2-arachidonoylglycerol protects against cerebral ischemia by reducing inflammation and neuronal damage,” published in 2003. The researchers showed that increasing 2-AG levels after brain ischemia significantly reduced brain edema, infarct size, and neuronal death, while blocking 2-AG worsened outcomes.

What this tells us is profound. The brain already knows how to protect itself. It uses 2-AG as an emergency signal to restore order when chaos hits. Supporting ECS balance does not introduce something foreign; it amplifies a system designed for survival. When the brain is injured, 2-AG shows up first, quietly doing the work most never see, keeping neurons alive long enough for healing to begin.

-Mike Robinson, The Researcher OG

12/23/2025

📅 December 18th marks a historic turning point in American healthcare.

On that day, President Donald J. Trump formally initiated the process to remove cannabis from Schedule I of the Controlled Substances Act, while also calling on Congress to modernize federal policy around hemp-derived cannabinoid products, including full-spectrum CBD.

For those of us who have dedicated our lives to cannabinoid therapeutics, nursing leadership, patient advocacy, and ethical access—this moment has been a long time coming.

This is not about hype. This is about science, compassion, regulation, and responsible care finally coming into alignment.

🌿 A new era of cannabis care is emerging—and healthcare must lead with knowledge, integrity, and compassion.

👉 Read more in the comments:
A New Era for Cannabis Care: What Rescheduling Means for Nurses, Patients & the Future of Healing - Links in the comment section

12/22/2025

Amen!!

Peripheral neuropathy is one of those conditions that does not always scream loud, but it never truly shuts up. Tingling, burning, numbness, electric pain, weakness, loss of temperature sense, and that constant reminder that the nerves are not communicating the way they should. For many patients, conventional medicine offers symptom management at best, often wrapped in drugs that dull the body while never addressing the underlying signaling breakdown.

This is where cannabinoids enter the conversation in a way that makes biological sense. The ECS, our Master Regulator, is deeply involved in peripheral nerve signaling, immune modulation, and pain perception. CB1 receptors are present along peripheral nerve pathways and influence how pain signals are transmitted to the brain, while CB2 receptors are heavily involved in immune response and neuroinflammation, two key drivers of neuropathic pain.

A well-known clinical trial published in 2015 in The Journal of Pain titled “Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual participant data” showed that cannabinoids significantly reduced neuropathic pain compared to placebo, even in patients who had failed multiple other treatments. Importantly, the study highlighted that cannabinoids worked differently from opioids or gabapentinoids, improving pain without completely disconnecting sensory awareness.

What makes cannabinoids unique in neuropathy is that they do not simply block pain. They modulate it. They influence ion channels, inflammatory signaling, and neurotransmitter release in damaged nerves, helping calm hyperexcitable pathways while supporting overall neural communication. Cannabinoids like THC, CBD, CBG, and CBGa each play different roles depending on the patient’s ECS tone, the cause of nerve damage, and the level of inflammation involved.

This explains why some patients experience reduced burning, improved sleep, and better motor control rather than just numbness. The goal is not to shut off the nerves. The goal is to restore functional signaling where possible and reduce the inflammatory noise that keeps nerves firing incorrectly.

Peripheral neuropathy is not a single disease, and there is no single cannabinoid answer. What works is respecting the complexity of the nervous system and working with it instead of against it. When cannabinoids are used to support ECS Balance rather than overwhelm receptors, patients often find relief that feels more natural and sustainable.

That is not masking symptoms. That is helping the nervous system remember how to communicate again. Reach out and let’s talk if you need information about cannabinoids and this issue.

-Mike Robinson, The Researcher OG

12/22/2025

A physician-led medical cannabis clinic established within a geriatric primary care practice supported diverse older adults with complex medical needs over 30 months. This integration helped assess risks, manage drug interactions, and improve communication with other healthcare providers, enhancing safety. The clinic model showed that combining medical cannabis with primary care for seniors is a viable approach. http://ms.spr.ly/6181tcLHN

12/21/2025

Amen!!!

A recent Brazilian clinical trial, published in the Journal of Alzheimer’s Disease and widely reported in December 2025, marks a groundbreaking development in exploring cannabis for Alzheimer’s treatment.

Researchers at the Federal University of Latin American Integration conducted a phase 2, randomized, double-blind, placebo-controlled study involving elderly patients aged 60-80 with mild Alzheimer’s disease.

Building on prior animal studies showing low-dose THC restoring cognition in aged mice and a 2022 case report where microdosing improved symptoms in one patient over 22 months, this trial tested daily oral microdoses of a balanced cannabis extract containing approximately 0.3 mg THC and 0.3 mg CBD—far below psychoactive levels.

Over 24-26 weeks, the treatment group showed stabilized cognitive function, as measured by the Mini-Mental State Examination (MMSE), while the placebo group experienced typical decline.

This pausing of progression represents the first human trial evidence of microdosing cannabinoids potentially halting Alzheimer’s-related cognitive deterioration without significant side effects.

Described as unprecedented, the approach leverages the endocannabinoid system’s role in neuroprotection, which naturally diminishes with age. Though promising, the study’s small sample size and limited scope to certain cognitive metrics highlight the need for larger, longer trials to confirm efficacy and safety.

Current Alzheimer’s therapies offer minimal benefit and often severe side effects, making this low-risk cannabinoid option a hopeful avenue amid rising dementia cases globally.

12/09/2025

Amen!!!

💯

12/05/2025

Findings are consistent with previous studies

12/04/2025

Amen

If …

12/02/2025

🙏